Shelly, Martin J.McDermott, ShaunaghO'Connor, O. J.Blake, Michael2013-02-252012Shelly, M. J., S. McDermott, O. J. O'Connor, and M. A. Blake. 2012. 18-fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma. ISRN Hematology 2012:456706.2090-441Xhttp://nrs.harvard.edu/urn-3:HUL.InstRepos:1034190718-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for posttreatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting.en-USJournal Article2013-02-2510.5402/2012/456706